http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-070516-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bde28565d28f037e78bf4a67776ee24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
| filingDate | 2008-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-070516-A1 |
| titleOfInvention | MODIFIED FORMULATION FOR THE ABSORPTION OF GABOXADOL |
| abstract | A pharmaceutical composition comprising gaboxadol or a pharmaceutically acceptable salt thereof and one or more inhibitors of PAT1 (for example: 5-hydroxy-tryptophan (5-HTP), L-Proline, D-Proline, Sarcosine, L-Alanine, D -Alanine, N-Methyl-L-alanine, N-Methyl-D-alanine, a- (methylamino) -isobutyric acid, Betaine, D-cycloserine, L-cycloserine, b-Alanine, Serotonin, L-tryptophan, D- tryptophan, tryptamine, indole-3-propionic acid) and / or one or more OAT inhibitors (for example quinurenate, xanthureate, 5-hydroxyindole acetate, p-aminohipurate, 6-carboxyfluorescein, benzylpenicillin, cefadroxil, cephamadol, cefazolin, cefoperazone, cefotaxime, cephalexin, cephalothin, cephradine, acyclovir, adefovir, cidofovir, ganciclovir, Tenofovir, valacyclovir, zidovudine, acetazolamide, bumetanide, chlorothiazide, ethacrynate, furosemide, hydrochlorothiazide, Methazolamide, Tridorometiazida, Acetaminophen, acetylsalicylate, diclofenac, diflunisal, Eodolac, flurbiprofen, Ibuprofen, lndomethacin, Ketopr Ofeno, Loxoprofen, Mefanamato, Naproxeno, Phenacetin, Piroxicam, Salicylate, Sulidac). In addition, a pharmaceutical composition comprising from about 0.5 mg is taught. at about 50 mg. of gaboxadol or a pharmaceutically acceptable salt thereof, where the composition provides an in vivo plasma profile comprising an average Tmax that is greater than about 20 minutes. These compositions allow an altered absorption of gaboxadol and thus minimize the peak concentration, extend the Tmax and in special situations also extend the phase of elimination of the pharmacokinetic profile (ie, increase the AUC). |
| priorityDate | 2007-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 119.